Eli Lilly CEO David Ricks on Q2 results: Seeing unbelievable demand for Zepbound and Mounjaro

Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion, demand outlook for Zepbound and Mounjaro, state of the weight loss drug competition, and more.

Aug 8, 2024 - 21:00

0 8

Eli Lilly CEO David Ricks on Q2 results: Seeing unbelievable demand for Zepbound and Mounjaro

Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion, demand outlook for Zepbound and Mounjaro, state of the weight loss drug competition, and more.

Tags:

Previous Article

Airbus North America CEO Robin Hayes on production ramp, travel demand outlook

IRS processing more ERC claims, moves moratorium date to Jan. 31, 2024

admin

admin

This website uses cookies to enhance your browsing experience. By continuing to use this site, you consent to the use of cookies. Please review our Privacy Policy for more information on how we handle your data.